TherapeuticsMD Finds New Exit With Mayne Pharma Licensing Pact

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

After failure to close of a potential $177m buyout by EW Pharma, TherapeuticsMD will resolve its debt by selling its three-product women’s health portfolio to Mayne.

Sell-off
TherapeuticsMD finds a buyer for its women's health portfolio • Source: Shutterstock

Despite missing out on a proposed acquisition priced at about four times its share price at the time of offer, TherapeuticsMD Inc. has found an exit for its shareholders by selling off its women’s health care portfolio to Australia’s Mayne Pharma International Pty. Ltd. at terms that come close to what the unsuccessful tender offer by EW Healthcare would have brought, along with earn-out potential that means the new deal could be an improvement on the failed buyout’s valuation.

[Sidebar#SC146471]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.